Only the PRISMAFLEX system truly provides the slow, continuous treatment critically ill patients require.
Accurate Fluid Management
Designed for the critically ill patient, clinicians can monitor how much therapy the patient is receiving within 7 mL of fluid accuracy, at any given time.
Uses a highly accurate, scale-based fluid management system (+/- 300 mL/24 hrs). We recommend a comparison of our accuracy specification to other systems for your consideration.¹
Filter Visibility
Visibility of filter and lines enables continual viewing of hemofilter and circuit integrity.
A range of filters offers individualized options for patient care including our M series with the AN69 membrane.
Our automated barcode recognition system allows you use the correctly selected set for your patient.
 
 
   
Automated Functionality
Scale-based systems allow for real-time automated measuring of fluid loss/gain.
Provides automatic, real-time tracking of all relevant pressures including filter pressure and transmembrane pressure (TMP).
Automatic air removal during therapy delivery prevents downtime— eliminates circuit downtime that may lead to premature clotting due to static blood while manual air removal is conducted.
Automated and integrated anticoagulation option.
Integrated, Real-Time Data
Efficiency through real-time presentation of data and storage of treatment history helps ensure patient safety, clear understanding of patient status and treatment parameters.
Displays both prescribed and actual therapy dosage.
Access up to 24 hours of treatment history.
 
 
 
 
 
 
Featured Presentation
CRRT in the Era of Drug Shortages
 
 
 
Want more information?
Speak with a Baxter representative or
connect with us at an event.
Acute Therapies Institute
This initiative brings together the kidney care
community to learn from industry experts and
share best practices.
 
 
 
The PRISMAFLEX Control Unit is intended for:
Continuous Renal Replacement Therapy (CRRT) for patients weighing 20 kilograms or more with acute renal failure and/or fluid overload.
Therapeutic Plasma Exchange (TPE) therapy for patients weighing 20 kilograms or more with diseases where fluid removal of plasma components is indicated.
Rx Only. For safe and proper use of products mentioned herein refer to the appropriate Instructions for Use or Operator's Manual.

PHOXILLUM Renal Replacement Solution Indications and Important Risk Information

Indications
PHOXILLUM solution is indicated in pediatric and adult patients for use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances. It may also be used in case of drug poisoning when CRRT is used to remove dialyzable substances.

Important Risk Information
PHOXILLUM solution can affect electrolytes and volume and may result in hyperkalemia or hyperphosphatemia. Monitor hemodynamic status and fluid inputs and outputs, potassium, phosphorous, calcium, other electrolytes and acid-base balance throughout the procedure. Abnormalities may be corrected by changing the formulation of replacement solution and/or dialysate, supplementation, or adjusting flow rates appropriately. PHOXILLUM replacement solutions contain hydrogen phosphate, a weak acid that may increase the risk of metabolic acidosis. PHOXILLUM solution can effect blood glucose levels resulting in hypo- or hyper-glycemia depending upon the dextrose content of the replacement solution. Monitor blood glucose levels regularly. Patients may require initiation of or modification of antidiabetic therapy or other corrective measures during treatment.

PRISMASOL Renal Replacement Solution

Indications
PRISMASOL Renal Replacement Solution is indicated in pediatric and adult patients for use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace plasma volume removed by ultrafiltration and to correct electrolytes and acid-base imbalances. PRISMASOL Solution may also be used in case of drug poisoning when CRRT is used to remove dialyzable substances.

Important Risk Information
PRISMASOL Renal Replacement Solution is contraindicated in patients with known hypersensitivities to this product.
PRISMASOL Solution can affect electrolytes and volume and may result in hyperkalemia or   hyperphosphatemia. Monitor hemodynamic status and fluid inputs and outputs, potassium, phosphorous, other electrolytes and acid-base balance throughout the procedure. Abnormalities may be corrected by changing the formulation of replacement solution and/or dialysate, supplementation, or adjusting flow rates appropriately. The use of PRISMASOL Solutions containing dextrose can affect blood glucose levels resulting in hypo- or hyper-glycemia depending upon the dextrose content of the replacement solution. Patients may require initiation of or modification of antidiabetic therapy or other corrective measures during treatment.
 
Please see PHOXILLUM and PRISMASOL Solutions full Prescribing Information.
1 Prismaflex Operator's Manual.